查詢結果分析
相關文獻
- Clinical Trial of a GMP Drug-Gemd (Gemfibrozil)
- 高脂血症藥物--膽酸結合劑
- 美國使用降高脂血症藥物的現況
- 高脂血症之藥物治療
- Flutamide-Induced Liver Injury: A Case Report
- Outcome of Graves' Disease after Antithyroid Drug Treatment in Taiwan
- 簡介呃逆的藥物治療
- Intrathecal Opioids Provide Satisfactory Conditions in Labor Analgesia and Spinal Anesthesia for Cesarean Section
- 臺灣地區藥物濫用社會成本推估初報
- In Vitro Effects of Various Neuropharmacological Agents on the Motility of Adult Clonorchis Sinensis
頁籤選單縮合
題 名 | Clinical Trial of a GMP Drug-Gemd (Gemfibrozil)=Gemfibrozil (Gemd)臨床試驗 |
---|---|
作 者 | 吳晉祥; 楊宜青; 盧豐華; 張智仁; | 書刊名 | 臺灣家庭醫學雜誌 |
卷 期 | 10:3 2000.09[民89.09] |
頁 次 | 頁109-118 |
分類號 | 418.227 |
關鍵詞 | 高脂血症; 藥物; Gemfibrozil; Primary dyslipidemia; Effect; Adverse reaction; |
語 文 | 英文(English) |
中文摘要 | Gemfibrozil為治療高脂血症病人,重要的常用藥物之一,除可有效治療高膽固醇血症外,更被推薦為高三酸甘油脂血之第一線用藥。本二之目的在於評估Gemfibrozil一天兩次對高脂血症病人的療效全性。我們預計選擇Type IIb、III及IV之高脂血症病人45例,以隨機、雙盲、安慰劑控制、二組平行試驗設計,引入經診斷且符合條件之病患,每位病患於試驗開始前6週,均無使用抗高血脂藥物。再以亂數分配將病患分成兩組,一組(治療組)患者投予Gemfibrozil,另一組(對照組)患者投予安慰劑,投予方式皆為一天二次、一次一粒口服給予。 結果顯示經亂數分配的治療組與對黨組各有23及22位。在12週藥物治療過程中,完成本試驗,治療組與對照組各為17人;因藥物不適反應及病人本線無意願繼續參加而退出者,治療組各有1及5人,對照組分別有4及1人。經12週藥物後,結果顯示治療組於藥品試驗後的血中膽固醇與三酸甘油脂值比試驗前明顯示降,試驗後的血中高密度脂蛋白值也比試驗前高;而對照組於藥品試驗前後之血脂值均無差異。又治療組與對照組於試驗後血中膽固醇值變化比例有顯著差異;兩組血中三酸甘油脂值變化比例也有明顯差異;至於兩組血中高密度脂蛋白值變化之比例則無顯著差異。 本研究中發生的不適反應以骨腸系統最多,治療組且對對照組各有2人與3人,兩組間並無差異。就皮膚與中樞神經系統之不適反應而言,治療組並無不適反應,但對照組有1人皮膚發疹,2人頭暈。在骨骼肌肉系統之不適反應、對血液學、肝與腎功能的變化,在治療組與對照組均無顯著影響。 以上結果顯示Gemfibrozil一天二次對高脂血症病人的血中膽固醇與三酸甘油脂值下降及高密度脂蛋白值的提升有其療效,尤其是對高三酸甘油脂血症。就安全性與副作用而言,除胃腸不適反應比例稍高外,並無其他明顯的副作用。 |
英文摘要 | Gemfibrozil is the drug of choice in the treatment of dyslipdemia for primary care physicians because of lower daily cost. Previous results in Taiwanese subjects were inconsistent with foreign reports. To evaluate the efficacy and safety of gemfibrozil, we conducted a randomized, double-blind, placebo-controlled study in Taiwanese subjects with primary dyslipdemia. Forthy-five subjects with type IIb, III or IV dyslidemia were eligible and given either gemfibrozil or placebo for 12 weeks. Based on the blocked random number generation program, the treatment and control groups included 23 and 22 subjects. All partisans received regular follow-up in the outpatient clinic every 4 weeks. The laboratory tests included blood chemistry and hematology data. In each of the treatment and control groups, 17 and 17 subjects completed the study, 1 and 4 subject failed to complete the study due to adverse drug reactions, and 5 and 1 subjects were not complaint with drug therapy, respectively. The result revealed a statistically significant decrease of total cholesterol, triglyceride and increase of HDL-cholesterol in the treatment group. The effects of gemibrozil in decrease of total cholesterol and triglyceride were found by 9.9% and 45.4%, respectively, and in increase of HDL-cholesterol was found by 9.7%. The gastrointestinal adverse events were not significantly different between treatment (11.1%) and control groups (14.2%). No other adverse event was found in the treatment group. In conclusion, gemfibrozil (Gemd) at a dose of 600mg twice daily is an effective and well-tolerated agent in reducing total cholesterol and triglyceride and raising HLD-cholesterol for subjects with dyslipidemia, especially those with elevated triglyceride levels. |
本系統中英文摘要資訊取自各篇刊載內容。